Corey K. Goldman
University of Alabama at Birmingham
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Corey K. Goldman.
Neurosurgery | 1997
Corey K. Goldman; Bharara S; Cheryl A. Palmer; Jiri J. Vitek; Jui-Chang Tsai; Weiss Hl; George Yancey Gillespie
OBJECTIVE:Vascular permeability factor/vascular endothelial growth factor(VPF/VEGF), an endothelial cell-specific cytokine, induces proliferation of endothelial cells and increases vascular permeability dramatically. All gliomas secrete significant amounts of VEGF, whereas meningiomas are variable i
International Journal of Cancer | 2002
Kazuo Shirakawa; Masabumi Shibuya; Yuji Heike; Shigemitsu Takashima; Ichiro Watanabe; Fumio Konishi; Fujio Kasumi; Corey K. Goldman; Kenneth A. Thomas; Andrew J. Bett; Masaaki Terada; Hiro Wakasugi
Inflammatory breast cancer (IBC) is a specific type of breast tumor that generally has a poor prognosis, in spite of recent advances in treatment. In the present study, semiquantitative reverse transcriptase polymerase chain reaction examination of resected specimens showed that angiogenic factors, not lymphangiogenic factors, are overexpressed in IBC tumors, compared with non‐IBC tumors. Immunohistochemical analysis of the specimens revealed a significantly higher population of tumor‐infiltrating (TI) endothelial cells (ECs) or endothelial precursor cells (EPCs) in tumor‐associated stroma of IBC specimens than in non‐IBC specimens. In a previous study, we examined the phenotype of host cells in response to transplanted IBC cells, using an established human IBC xenograft model (WIBC‐9) (Shirakawa et al., Cancer Res 2001;61:445–51). The data obtained in that study are consistent with the findings of the present study. To explore the therapeutic potential of blocking vascular endothelial growth factor (VEGF) and angiopoietin (Ang) pathways in IBC, established vectors encoding soluble Flt‐1 (sFlt‐1) and soluble Tie2 (sTie2) were injected directly into WIBC‐9. Both vectors produced growth inhibition ratios of WIBC‐9 that were significantly higher than those of a non‐IBC xenograft (MC‐5). Also, both vectors suppressed WIBC‐9 lung metastases. The efficacy correlated with the number of TI ECs/EPCs, which was determined by fluorescence‐activated cell sorting. These ECs/EPCs incorporated acetylated lipoprotein and were integrated within a HUVEC monolayer in vitro culture on day 5.
Journal of Neurosurgery | 1995
Jui-Chang Tsai; Corey K. Goldman; G. Y. Gillespie
Cancer Research | 1997
Corey K. Goldman; Buck E. Rogers; Joanne T. Douglas; Barbara A. Sosnowski; Wenbin Ying; Gene P. Siegal; Andrew Baird; Julie A. Campain; David T. Curiel
Nature Biotechnology | 1997
Meizhen Feng; William H. Jackson; Corey K. Goldman; Claudine Rancourt; Minghui Wang; Sandra K. Dusing; Gene P. Siegal; David T. Curiel
Nature Biotechnology | 1997
Corey K. Goldman; Soroceanu L; Smith N; Gillespie Gy; Shaw W; Burgess S; Bilbao G; Curiel Dt
Journal of Investigative Dermatology | 1995
Corey K. Goldman; Jui-Chang Tsai; Liliana Soroceanu; G. Yancey Gillespie
Journal of The Formosan Medical Association | 1999
Jui-Chang Tsai; Yi-Yun Hsiao; Lee-Jene Teng; Chia-Tung Shun; Chin-Tin Chen; Corey K. Goldman; Ming-Chien Kao
International Journal of Cancer | 1998
Seiji Hama; Yuji Heike; Ichiro Naruse; Minako Takahashi; Hiroyuki Yoshioka; Kazunori Arita; Kaoru Kurisu; Corey K. Goldman; David T. Curiel; Nagahiro Saijo
Biochemical and Biophysical Research Communications | 2003
Jui-Chang Tsai; Lee-Jene Teng; Chin-Tin Chen; Tse-Ming Hong; Corey K. Goldman; G. Yancey Gillespie